Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 10/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648387 | 0.83 | WNT3A (0.38) | CYP1A2CYP2C19WNT3ATNKS2KDM4E | |
| SCHEMBL16637692 | 0.81 | HTR2A (0.38) | CYP1A2CYP2C19WNT3ATNKS2PDK1 | |
| SCHEMBL29588176 | 0.81 | CYP1A2 (0.36) | CYP1A2CYP2C19WNT3ATNKS2PDK1 | |
| SCHEMBL29903126 | 0.70 | CYP1A2 (0.37) | CYP1A2CYP2C19WNT3ATNKS2 | |
| SCHEMBL20584210 | 0.69 | PPARG (0.44) | TNKS2ALDH1A1ALOX15TSHR | |
| SCHEMBL17986449 | 0.66 | TNKS2 (0.57) | WNT3ATNKS2ALDH1A1 | |
| SCHEMBL2708822 | 0.66 | ATM (0.35) | KDM4E | |
| SCHEMBL16916019 | 0.66 | ACHE (0.40) | KDM4EALDH1A1ALOX15TSHRPOLB | |
| SCHEMBL18343108 | 0.65 | TNKS2 (0.32) | WNT3ATNKS2KDM4EPDK1 | |
| SCHEMBL4906472 | 0.64 | CYP1A2 (0.35) | CYP1A2CYP2C19KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | CYP1A2 1319/4885CYP2C19 1136/4885WNT3A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.